{"id":"CHEMBL1010","canonicalSmiles":"CO/N=C(\\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(COC(C)=O)CS[C@H]12)c1csc(N)n1.[Na+]","inchiKey":"AZZMGZXNTDTSME-JUZDKLSSSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"CEFOTAXIME SODIUM","yearOfFirstApproval":1981,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1730","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Cefcil","Cefotaxime","Cefotaxime sodium","Claforan","Pretor"],"synonyms":["Cefotaxime sodium","Cefotaxime sodium salt","HR 756","HR-756","RU 24756","RU-24756"],"crossReferences":{"DailyMed":["cefotaxime%20sodium"],"PubChem":["50106035","56422770","85149186","85273722"],"chEBI":["3498"]},"count":1,"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1981 and has 1 investigational indication."}
{"id":"CHEMBL105318","canonicalSmiles":"Cc1cn([C@H]2C[C@H](F)[C@@H](CO)O2)c(=O)[nH]c1=O","inchiKey":"UXCAQJAQSWSNPQ-XLPZGREQSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ALOVUDINE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Alovudine","CL 184,824","CL 184824","CL-184,824","CL-184824","NSC-140025"],"crossReferences":{"PubChem":["144205929","170466324"],"Wikipedia":["Alovudine"],"drugbank":["DB06198"]},"count":1,"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL1057","canonicalSmiles":"O=C1OC2(c3ccc(O)cc3Oc3cc(O)ccc32)c2ccccc21","inchiKey":"GNBHRKFJIUUOQI-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1057","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["144207049","144213816","26755297","29216383"],"drugbank":["DB00693"],"chEBI":["31624"]},"childChemblIds":["CHEMBL1200433"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1084172","canonicalSmiles":"O=C(O)C(c1ccccc1)(c1ccccc1)c1ccccc1.OCc1cc([C@@H](O)CNCCCCCCOCCOCc2c(Cl)cccc2Cl)ccc1O","inchiKey":"KLOLZALDXGTNQE-JIDHJSLPSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"VILANTEROL TRIFENATATE","yearOfFirstApproval":2013,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1198857","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["GW-642444M","GW642444M","Vilanterol trifenatate"],"crossReferences":{"DailyMed":["vilanterol%20trifenatate"],"chEBI":["75040"]},"count":4,"approvedIndications":["EFO_0000270","EFO_0000464","EFO_0006505","EFO_0000341"],"linkedTargets":{"rows":["ENSG00000169252"],"count":1},"linkedDiseases":{"rows":["EFO_0000270","EFO_0000464","EFO_0006505","EFO_0000341"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 4 approved indications."}
{"id":"CHEMBL11","canonicalSmiles":"CN(C)CCCN1c2ccccc2CCc2ccccc21","inchiKey":"BCGWQEUPMDMJNV-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"IMIPRAMINE","yearOfFirstApproval":1959,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Imipramine","Janimine","NSC-169866","ORG-2463","Pramine","Presamine","Tofranil","Tofranil-PM","Trimipramine maleate impurity, imipramine-"],"crossReferences":{"DailyMed":["imipramine%20hydrochloride","imipramine%20pamoate"],"PubChem":["104171178","11111330","11111331","124880469","144203725","170464777","26751600","50100256","50104254","90341377"],"TG-GATEs":["69"],"Wikipedia":["Imipramine"],"drugbank":["DB00458"],"chEBI":["47499"]},"childChemblIds":["CHEMBL3989845","CHEMBL1692"],"count":13,"approvedIndications":["EFO_0003761"],"linkedTargets":{"rows":["ENSG00000108576","ENSG00000103546"],"count":2},"linkedDiseases":{"rows":["MONDO_0002009","HP_0000726","EFO_0004278","MONDO_0007254","EFO_0009562","EFO_0003948","EFO_0008623","MONDO_0002050","EFO_0010282","EFO_0004287","EFO_0009687","EFO_0003761","HP_0003419","EFO_0000612","HP_0100749","EFO_0005230","EFO_0000692"],"count":17},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and is indicated for unipolar depression and has 12 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1133","canonicalSmiles":"CCN(CC)CC#CCOC(=O)C(O)(c1ccccc1)C1CCCCC1.Cl","inchiKey":"SWIJYDAEGSIQPZ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"OXYBUTYNIN CHLORIDE","yearOfFirstApproval":1975,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1231","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Ditropan","Ditropan xl","Gelnique","Oxybutynin chloride"],"synonyms":["5058","MJ 4309-1","MJ-4309-1","Oxybutynin chloride","Oxybutynin hydrochloride"],"crossReferences":{"DailyMed":["oxybutynin%20chloride"],"PubChem":["144204058","50106787","50106788","56422498","855604"],"chEBI":["7857"]},"count":2,"approvedIndications":["EFO_1000781"],"linkedTargets":{"rows":["ENSG00000133019","ENSG00000181072"],"count":2},"linkedDiseases":{"rows":["EFO_0006865","HP_0000020","EFO_1000781","EFO_0001663"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1975 and is indicated for overactive bladder and has 1 investigational indication."}
{"id":"CHEMBL1171754","canonicalSmiles":"O=C(c1ccc(Oc2ccc(F)cc2)nc1)N1CCCN(C2CCC2)CC1","inchiKey":"IQOWHZHNGJXGHG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"JNJ-39220675","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Jnj-39220675"],"crossReferences":{"drugbank":["DB12929"]},"count":1,"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL1200531","canonicalSmiles":"CCC(=O)N(c1ccccc1)C1(COC)CCN(CCn2nnn(CC)c2=O)CC1.Cl","inchiKey":"AQORHZJDCHLLJN-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"ALFENTANIL HYDROCHLORIDE","yearOfFirstApproval":1986,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL634","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Alfenta","Alfentanil","Rapifen","Rapifen conc","Rapifen dilute","Rapifen intensive care"],"synonyms":["Alfentanil hydrochloride","Alfentanil hydrochloride cii","Alfentanil hydrochloride monohydrate","R 39,209","R 39209","R-39,209","R-39209"],"crossReferences":{"PubChem":["144206431","85273815"]},"linkedTargets":{"rows":["ENSG00000112038"],"count":1},"linkedDiseases":{"rows":["EFO_0003843"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1986. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1200776","canonicalSmiles":"C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12.Cl","inchiKey":"QANQWUQOEJZMLL-PKLMIRHRSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CINACALCET HYDROCHLORIDE","yearOfFirstApproval":2004,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1201284","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Mimpara","Sensipar"],"synonyms":["AMG-073","AMG-073 HCL","AMG073 HCL","AMG073 HYDROCHLORIDE","Cinacalcet hydrochloride"],"crossReferences":{"DailyMed":["cinacalcet%20hydrochloride"],"PubChem":["144206207","170465336"],"chEBI":["48391"]},"count":2,"linkedTargets":{"rows":["ENSG00000036828"],"count":1},"linkedDiseases":{"rows":["EFO_1001173","EFO_0000673"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 2 investigational indications."}
{"id":"CHEMBL1200866","canonicalSmiles":"FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br","inchiKey":"WTWWXOGTJWMJHI-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PERFLUBRON","yearOfFirstApproval":1993,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Imagent"],"synonyms":["Perflubron","Perfluorooctylbromide","Pfob"],"crossReferences":{"PubChem":["144205906","170465144","29217975"],"drugbank":["DB05791"],"chEBI":["38803"]},"count":1,"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1993 and has 1 investigational indication."}
{"id":"CHEMBL1201004","canonicalSmiles":"Br.COc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3","inchiKey":"MISZALMBODQYFT-URVXVIKDSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DEXTROMETHORPHAN HYDROBROMIDE","maximumClinicalTrialPhase":0,"parentId":"CHEMBL52440","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1201018","canonicalSmiles":"N[C@@H](C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(Cl)CS[C@H]12)c1ccccc1.O","inchiKey":"WKJGTOYAEQDNIA-IOOZKYRYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CEFACLOR","yearOfFirstApproval":1979,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL680","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Bacticlor mr","Ceclor","Ceclor cd","Cefaclor","Distaclor","Distaclor mr","Keftid","Raniclor"],"synonyms":["COMPOUND 99638","COMPOUND-99638","Cefaclor","Cefaclor monohydrate","J01DC04"],"crossReferences":{"DailyMed":["cefaclor"]},"count":7,"approvedIndications":["EFO_0003106","EFO_0003103","EFO_0000771","EFO_0004992","HP_0011110","MONDO_0002258"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1979 and has 6 approved and 1 investigational indication."}
{"id":"CHEMBL1201064","canonicalSmiles":"CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C","inchiKey":"YRFXGQHBPBMFHW-SBTZIJSASA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FLUOROMETHOLONE ACETATE","yearOfFirstApproval":1986,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Flarex"],"synonyms":["Fluorometholone acetate","U-17,323","U-17323"],"crossReferences":{"DailyMed":["fluorometholone%20acetate"],"PubChem":["100431"],"chEBI":["78354"]},"count":3,"approvedIndications":["EFO_0009552","EFO_0003894","EFO_0005752"],"linkedTargets":{"rows":["ENSG00000113580"],"count":1},"linkedDiseases":{"rows":["EFO_0009552","EFO_0003894","EFO_0005752"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and has 3 approved indications."}
{"id":"CHEMBL1201262","canonicalSmiles":"CNCC(O)c1ccc(OC(=O)C(C)(C)C)c(OC(=O)C(C)(C)C)c1","inchiKey":"OCUJLLGVOUDECM-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DIPIVEFRIN","yearOfFirstApproval":1980,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["DPE","Dipivalyl epinephrine","Dipivefrin","Dipivefrine"],"crossReferences":{"Wikipedia":["Dipivefrine"],"drugbank":["DB00449"],"chEBI":["4646"]},"childChemblIds":["CHEMBL1200833"],"count":1,"approvedIndications":["EFO_0000516"],"linkedTargets":{"rows":["ENSG00000184160","ENSG00000274286","ENSG00000169252","ENSG00000171873","ENSG00000170214","ENSG00000120907","ENSG00000043591","ENSG00000188778","ENSG00000150594"],"count":9},"linkedDiseases":{"rows":["EFO_0000516"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1980 and is indicated for glaucoma."}
{"id":"CHEMBL1201513","drugType":"Oligosaccharide","blackBoxWarning":false,"name":"HEPARIN CALCIUM","yearOfFirstApproval":1982,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Calciparine","Uniparin ca"],"synonyms":["Heparin calcium","Heparin calcium salt"],"count":5,"approvedIndications":["EFO_0003966","HP_0002619","HP_0004419"],"linkedTargets":{"rows":["ENSG00000117601"],"count":1},"linkedDiseases":{"rows":["EFO_0003966","EFO_1000965","HP_0002619","HP_0004419","EFO_1000954"],"count":5},"description":"Oligosaccharide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 3 approved and 2 investigational indications."}
{"id":"CHEMBL1201723","drugType":"Unknown","blackBoxWarning":false,"name":"SINECATECHINS","yearOfFirstApproval":2006,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Veregen"],"synonyms":["Sinecatechins"],"crossReferences":{"DailyMed":["sinecatechins"],"DrugCentral":["4785"]},"count":3,"approvedIndications":["EFO_0000763"],"description":"Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and is indicated for viral disease and has 2 investigational indications."}
{"id":"CHEMBL1201828","drugType":"Antibody","blackBoxWarning":true,"name":"ECULIZUMAB","yearOfFirstApproval":2007,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Soliris"],"synonyms":["5G1.1","ABP-959","Eculizumab","H5G1-1","H5G1.1","H5G1.1VHC+H5G1.1VLC","H5G11"],"crossReferences":{"DailyMed":["eculizumab"],"DrugCentral":["4969"],"Wikipedia":["Eculizumab"]},"count":18,"approvedIndications":["Orphanet_2134","EFO_0000540","Orphanet_447"],"linkedTargets":{"rows":["ENSG00000106804"],"count":1},"linkedDiseases":{"rows":["Orphanet_2134","EFO_0001365","EFO_1001311","EFO_0000540","MONDO_0004784","HP_0001873","EFO_0004599","EFO_0000565","Orphanet_93571","MONDO_0100096","MONDO_0001549","EFO_0000398","EFO_0003884","EFO_0009473","EFO_0007292","EFO_0004256","EFO_0004826","EFO_0004991","EFO_0000400","Orphanet_447"],"count":20},"description":"Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 3 approved and 15 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1213270","canonicalSmiles":"COC(=O)C1=C(C(=O)OC)[C@@H]2O[C@H]1C(c1ccc(O)cc1)=C2c1ccc(O)cc1","inchiKey":"CRLQCBACIMUGDZ-BGYRXZFFSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1213270","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07932"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL122055","canonicalSmiles":"O=C(O)c1ccc(-c2c(F)cccc2F)cc1","inchiKey":"CWWIIKLXUPZDOG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL122055","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB06935"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1223852","canonicalSmiles":"CC1=C(C)C(=O)C(CC[C@](C)(O)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C1=O","inchiKey":"LTVDFSLWFKLJDQ-IEOSBIPESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"Alpha-Tocopherylquinone","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Alpha-Tocopherylquinone"],"crossReferences":{"drugbank":["DB14094"]},"childChemblIds":["CHEMBL4293169"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1236315","canonicalSmiles":"O=C(O)[C@H](O)[C@@H](O)C(=O)O","inchiKey":"FEWJPZIEWOKRBE-JCYAYHJZSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TARTRATE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["E 334","E-334","FEMA NO. 3044","INS NO.334","INS-334","L-tartaric acid","NSC-62778","Tartaric acid","Tartrate"],"crossReferences":{"PubChem":["144210475","57264380"],"drugbank":["DB09459"],"chEBI":["15671"]},"count":1,"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL1241855","canonicalSmiles":"COc1cc(OC)c(/C=C/S(=O)(=O)Cc2ccc(OC)c(NCC(=O)O)c2)c(OC)c1","inchiKey":"OWBFCJROIKNMGD-BQYQJAHWSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"RIGOSERTIB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ON 01910","Rigosertib"],"crossReferences":{"drugbank":["DB12146"]},"childChemblIds":["CHEMBL2013119"],"count":6,"linkedTargets":{"rows":["ENSG00000181104"],"count":1},"linkedDiseases":{"rows":["EFO_0000198","EFO_1000172","EFO_0000616","EFO_1001779","EFO_0005922","MONDO_0008170","EFO_0000222","EFO_0000708","EFO_0000311","EFO_1000044","EFO_0000339","EFO_0000095","EFO_0000181","MONDO_0009179","EFO_0003811"],"count":15},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."}
{"id":"CHEMBL1289494","canonicalSmiles":"COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC","inchiKey":"SPMVMDHWKHCIDT-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TIVOZANIB","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Fotivda"],"synonyms":["ASP-4130","AV-951","KIL8951","KRN-951","Kil-8951","Krn-951","Tivozanib"],"crossReferences":{"PubChem":["124955473"],"Wikipedia":["Tivozanib"],"drugbank":["DB11800"]},"childChemblIds":["CHEMBL2105756","CHEMBL3426917"],"count":11,"approvedIndications":["EFO_0000616"],"linkedTargets":{"rows":["ENSG00000128052","ENSG00000102755","ENSG00000037280"],"count":3},"linkedDiseases":{"rows":["EFO_0000616","MONDO_0015686","MONDO_0008170","EFO_0000681","MONDO_0007254","EFO_1001968","EFO_0003060","EFO_0005221","MONDO_0008315","EFO_1001951","EFO_1001480","EFO_1000218","MONDO_0002158","EFO_0000182","EFO_0001421","EFO_0000519"],"count":16},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for neoplasm and has 10 investigational indications."}
{"id":"CHEMBL1328","canonicalSmiles":"CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O","inchiKey":"NEYNJQRKHLUJRU-DZUOILHNSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PENTAGASTRIN","yearOfFirstApproval":1974,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Peptavlon"],"synonyms":["AY-6608","ICI 50,123","ICI-50123","Pentagastrin"],"crossReferences":{"PubChem":["144207028","170465396"],"Wikipedia":["Pentagastrin"],"drugbank":["DB00183"]},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1974."}
{"id":"CHEMBL1384","canonicalSmiles":"NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O","inchiKey":"SBUJHOSQTJFQJX-NOAMYHISSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"KANAMYCIN","yearOfFirstApproval":1973,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Kanamycin"],"crossReferences":{"Wikipedia":["Kanamycin"],"drugbank":["DB01172"],"chEBI":["17630"]},"childChemblIds":["CHEMBL1446"],"count":5,"approvedIndications":["EFO_0000771","EFO_1001888"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and is indicated for bacterial disease and eye infection and has 3 investigational indications."}
{"id":"CHEMBL1477","canonicalSmiles":"COCc1c(C(C)C)nc(C(C)C)c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)c1-c1ccc(F)cc1","inchiKey":"SEERZIQQUAZTOL-ANMDKAQQSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CERIVASTATIN","yearOfFirstApproval":1997,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["United States"],"classes":["Musculoskeletal toxicity"," Nephrotoxicity"],"year":2001},"tradeNames":["Lipobay"],"synonyms":["Baycol","Cerivastatin","Lipobay"],"crossReferences":{"PubChem":["50111694"],"Wikipedia":["Cerivastatin"],"drugbank":["DB00439"],"chEBI":["3558"]},"childChemblIds":["CHEMBL1200563"],"count":1,"approvedIndications":["EFO_0000319"],"linkedTargets":{"rows":["ENSG00000113161"],"count":1},"linkedDiseases":{"rows":["EFO_0000319"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1997 and is indicated for cardiovascular disease. It was withdrawn in United States  in 2001 due to Musculoskeletal toxicity and  Nephrotoxicity."}
{"id":"CHEMBL148674","canonicalSmiles":"CCc1c(C(=O)C(N)=O)c2c(OCC(=O)O)cccc2n1Cc1ccccc1","inchiKey":"BHLXTPHDSZUFHR-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"VARESPLADIB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["LY-315920","LY315920","Varepladib","Varespladib","Varespladib sodium"],"crossReferences":{"PubChem":["174006184"],"Wikipedia":["Varespladib"],"drugbank":["DB11909"]},"childChemblIds":["CHEMBL2107809"],"count":1,"linkedTargets":{"rows":["ENSG00000188257"],"count":1},"linkedDiseases":{"rows":["Orphanet_232","EFO_0001645"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL153479","canonicalSmiles":"Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1","inchiKey":"JBDGDEWWOUBZPM-XYPYZODXSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"AMBROXOL","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Ambroxol","Ambroxol hydrochloride"],"crossReferences":{"PubChem":["29215331","50085991"],"Wikipedia":["Ambroxol"],"drugbank":["DB06742"]},"childChemblIds":["CHEMBL1514634"],"count":5,"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."}
{"id":"CHEMBL1625260","canonicalSmiles":"CCOC(=O)Nc1ccc2c(c1)N(C(=O)CN(C)C)c1ccccc1CC2","inchiKey":"KJAMZCVTJDTESW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TIRACIZINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Tiracizine"],"crossReferences":{"PubChem":["144206671"],"drugbank":["DB13635"]},"childChemblIds":["CHEMBL1590144"],"count":1,"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL1678","canonicalSmiles":"COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2.Cl","inchiKey":"XWAIAVWHZJNZQQ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DONEPEZIL HYDROCHLORIDE","yearOfFirstApproval":1996,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL502","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Aricept","Aricept evess","Aricept odt","Donepezil hydrochloride"],"synonyms":["BNAG","Donepezil hydrochloride","E-2020","E2020"],"crossReferences":{"DailyMed":["donepezil%20hydrochloride"],"PubChem":["144206087","170464858","26719734","49732006"],"chEBI":["4696"]},"count":12,"approvedIndications":["HP_0000726","EFO_0000249"],"linkedTargets":{"rows":["ENSG00000087085"],"count":1},"linkedDiseases":{"rows":["EFO_0005762","EFO_0004718","HP_0000726","EFO_0000249","EFO_1001454","EFO_0003821","EFO_0003758","EFO_0006792","EFO_0009267","Orphanet_778","HP_0100543","MONDO_0002050","EFO_0003884","EFO_0001064","EFO_1000158"],"count":15},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for alzheimer's disease and dementia and has 10 investigational indications."}
{"id":"CHEMBL1687","canonicalSmiles":"COc1cc2c3cc1Oc1cc(ccc1O)C[C@@H]1c4c(cc(OC)c(O)c4Oc4ccc(cc4)C[C@@H]3N(C)CC2)CC[N+]1(C)C.[Cl-]","inchiKey":"MHXYWXHKLBMJKL-QBYKQQEBSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TUBOCURARINE CHLORIDE","maximumClinicalTrialPhase":0,"parentId":"CHEMBL339427","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Tubocurarine Chloride"],"synonyms":["Tubocurarine Chloride"],"crossReferences":{"Wikipedia":["Tubocurarine_chloride"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1688529","canonicalSmiles":"C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C","inchiKey":"RPJPZDVUUKWPGT-FOIHOXPVSA-N","drugType":"Protein","blackBoxWarning":false,"name":"NIM811","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["NIM811","Nim811"],"crossReferences":{"Wikipedia":["NIM811"],"drugbank":["DB13068"]},"count":1,"description":"Protein drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL1712170","canonicalSmiles":"CCOc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@]314","inchiKey":"OGDVEMNWJVYAJL-LEPYJNQMSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ETHYLMORPHINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Ethylmorphine"],"crossReferences":{"PubChem":["144206163","50113064"],"drugbank":["DB01466"],"chEBI":["4902"]},"childChemblIds":["CHEMBL2107695"],"count":2,"description":"Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL1715","canonicalSmiles":"CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1.Cl","inchiKey":"GHUUBYQTCDQWRA-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"PIOGLITAZONE HYDROCHLORIDE","yearOfFirstApproval":1999,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL595","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Actos","Diabiom","Glidipion","Glizofar","Pioglitazone hydrochloride"],"synonyms":["Actos","Pioglitazone hydrochloride","STR-001","U-72107A"],"crossReferences":{"DailyMed":["pioglitazone%20hydrochloride"],"PubChem":["144204993","144210901","170465116","26748968","49681546"]},"count":8,"approvedIndications":["EFO_0001360"],"linkedTargets":{"rows":["ENSG00000132170"],"count":1},"linkedDiseases":{"rows":["EFO_0002618","HP_0002745","EFO_0003095","MONDO_0002009","EFO_0003884","EFO_0000253","EFO_0001360","EFO_0003060"],"count":8},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and is indicated for type ii diabetes mellitus and has 7 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1722","canonicalSmiles":"COC(=O)C(c1ccccc1)C1CCCCN1.Cl","inchiKey":"JUMYIBMBTDDLNG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"METHYLPHENIDATE HYDROCHLORIDE","yearOfFirstApproval":1955,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL796","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Adhansia xr","Aptensio xr","Concerta","Delmosart","Equasym","Equasym xl","Jornay pm","Matoride xl","Medikinet","Medikinet xl","Metadate cd","Metadate er","Methylin","Methylin er","Methylphenidate hydrochloride","Quillichew er","Quillivant xr","Ritalin","Ritalin la","Ritalin sr","Ritalin-sr","Tranquilyn","Xenidate xl"],"synonyms":["Aptensio xr","Methylphenidate HCl","Methylphenidate hydrochloride","NSC-169868","SPD-544","SPD544"],"crossReferences":{"DailyMed":["methylphenidate%20hydrochloride"],"PubChem":["144204737","144207507","17389819"],"chEBI":["31836"]},"count":7,"approvedIndications":["EFO_0003888"],"linkedTargets":{"rows":["ENSG00000103546","ENSG00000142319"],"count":2},"linkedDiseases":{"rows":["EFO_0003888","EFO_0003840","MONDO_0002050","EFO_0004216","MONDO_0045054","EFO_0003929","EFO_0003768","HP_0012378","EFO_0004242","EFO_0000311"],"count":10},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1955 and is indicated for attention deficit hyperactivity disorder and has 6 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1727","canonicalSmiles":"CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1","inchiKey":"ZAIPMKNFIOOWCQ-UEKVPHQBSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CEPHALEXIN","yearOfFirstApproval":1971,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Keflet","Keflex"],"synonyms":["66873","Cefalexin","Cephalexin","Keflet","Keflex","Keftab"],"crossReferences":{"DailyMed":["cephalexin"],"PubChem":["144205293","170464982","26719711","29215501"],"Wikipedia":["Cefalexin"],"drugbank":["DB00567"],"chEBI":["3534"]},"childChemblIds":["CHEMBL1200366","CHEMBL1200544"],"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1971."}
{"id":"CHEMBL1731","canonicalSmiles":"CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCN(S(C)(=O)=O)C3=O)c3ccccc3)C(=O)N2[C@H]1C(=O)O","inchiKey":"YPBATNHYBCGSSN-VWPFQQQWSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MEZLOCILLIN","yearOfFirstApproval":1981,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Baypen","Multocillin"],"synonyms":["BAY-F-1353","Mezlocillin"],"crossReferences":{"PubChem":["144206027"],"Wikipedia":["Mezlocillin"],"drugbank":["DB00948"],"chEBI":["6919"]},"childChemblIds":["CHEMBL1697708"],"count":2,"approvedIndications":["EFO_0000771"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and is indicated for bacterial disease and has 1 investigational indication."}
{"id":"CHEMBL1743021","drugType":"Antibody","blackBoxWarning":false,"name":"FORAVIRUMAB","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CR-4098","Foravirumab"],"description":"Antibody drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1743041","drugType":"Antibody","blackBoxWarning":false,"name":"MOGAMULIZUMAB","yearOfFirstApproval":2018,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Poteligeo"],"synonyms":["AMG-761","KM-8761","KM8761","KW-0761","Mogamulizumab","Mogamulizumab (genetical recombination)","Mogamulizumab-kpkc"],"crossReferences":{"DailyMed":["mogamulizumab-kpkc"],"DrugCentral":["5031"]},"count":11,"approvedIndications":["EFO_0000616","EFO_1001051","EFO_1000785"],"linkedTargets":{"rows":["ENSG00000183813"],"count":1},"linkedDiseases":{"rows":["EFO_0000211","EFO_0000616","MONDO_0019471","MONDO_0044889","EFO_0000270","EFO_0000182","EFO_0002913","EFO_1001051","EFO_0000313","EFO_0002426","EFO_1000785","EFO_0007527","EFO_0003060"],"count":13},"description":"Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 8 investigational indications."}
{"id":"CHEMBL1743048","drugType":"Antibody","blackBoxWarning":true,"name":"OBINUTUZUMAB","yearOfFirstApproval":2013,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Gazyvaro"],"synonyms":["AFUTUZUMAB","Afutuzumab","GA-101","GA101","HUMAB<CD20>","HUMABCD20","Obinutuzumab","R-7159","RG-7159","RO 5072759","RO 5072759 HUMAB<CD20>","RO-5072759","RO-5072759 HUMAB<CD20>"],"crossReferences":{"DailyMed":["obinutuzumab"],"DrugCentral":["4983"]},"count":20,"approvedIndications":["EFO_0000616","EFO_0000095","EFO_0000311"],"linkedTargets":{"rows":["ENSG00000156738"],"count":1},"linkedDiseases":{"rows":["EFO_0009441","EFO_0000616","EFO_0003086","MONDO_0013730","EFO_0005761","MONDO_0019465","EFO_0000403","EFO_1001469","EFO_0005952","EFO_1001951","EFO_0000311","EFO_0000565","EFO_0000309","EFO_0000304","EFO_0000096","MONDO_0001023","EFO_0000095","EFO_1000956","MONDO_0019088","EFO_0003884","EFO_0000574","EFO_1001051","MONDO_0018906","EFO_0000183","MONDO_0002083"],"count":25},"description":"Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 3 approved and 17 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1767408","canonicalSmiles":"O=c1ccn([C@@H]2O[C@H](COP(=O)([O-])OP(=O)([O-])OP(=O)([O-])OP(=O)([O-])OC[C@H]3O[C@@H](n4ccc(=O)[nH]c4=O)[C@H](O)[C@@H]3O)[C@@H](O)[C@H]2O)c(=O)[nH]1.[Na+].[Na+].[Na+].[Na+]","inchiKey":"OWTGMPPCCUSXIP-FNXFGIETSA-J","drugType":"Small molecule","blackBoxWarning":false,"name":"DIQUAFOSOL TETRASODIUM","maximumClinicalTrialPhase":3,"parentId":"CHEMBL221326","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["DE-089","Diquafosol sodium","Diquafosol tetrasodium","Diquafosol tetrasodium salt","INS 365","INS365","KPY-998"],"crossReferences":{"Wikipedia":["Diquafosol"]},"count":1,"linkedTargets":{"rows":["ENSG00000186912","ENSG00000169860","ENSG00000175591","ENSG00000171631"],"count":4},"linkedDiseases":{"rows":["EFO_1000906"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL1774080","canonicalSmiles":"O=C1CCc2ccc(OCCCCN3CCN(c4cccc5ccccc45)CC3)nc2N1","inchiKey":"QGNOXTFZOLDODX-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PF-00217830","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["J2.975.999E","PF-00217830","PF-217830","Pf-00217830"],"crossReferences":{"drugbank":["DB12998"]},"count":1,"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL178","canonicalSmiles":"COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1","inchiKey":"STQGQHZAVUOBTE-VGBVRHCVSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"DAUNORUBICIN","yearOfFirstApproval":1979,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Daunoxome"],"synonyms":["Cerubidine","Daunorubicin","Daunoxome","Epirubicin hydrochloride impurity, daunorubicin-","FI 6339","FI-6339","NSC-83142","RP 13057","RP-13057","Valrubicin impurity, daunorubicin"],"crossReferences":{"DailyMed":["daunorubicin","daunorubicin%20hydrochloride"],"PubChem":["11114094","144204447","170465048","29215022"],"Wikipedia":["Daunorubicin"],"drugbank":["DB00694"],"chEBI":["41977"]},"childChemblIds":["CHEMBL1563","CHEMBL1200475"],"count":20,"approvedIndications":["EFO_0000616","EFO_0000222"],"linkedTargets":{"rows":["ENSG00000131747"],"count":1},"linkedDiseases":{"rows":["MONDO_0000873","MONDO_0044903","EFO_0003812","EFO_0000558","MONDO_0007254","EFO_1001945","EFO_0000209","EFO_0005952","EFO_1001052","MONDO_0003541","EFO_0000565","EFO_0004251","EFO_0000339","EFO_0004289","EFO_0000330","MONDO_0020743","EFO_0000094","EFO_0000479","EFO_0000198","EFO_0000221","EFO_0000616","EFO_0003802","EFO_1001779","EFO_0000220","MONDO_0019457","EFO_0000222","EFO_0000223","EFO_1001946","MONDO_0000870","MONDO_0044881","EFO_0000224","EFO_0002429","EFO_0003025","EFO_0003029","EFO_1001934","EFO_0004239","EFO_0003028","MONDO_0044917","EFO_1001936","EFO_0000574","EFO_1001947","EFO_0000218","EFO_0000691","EFO_1002001","MONDO_0004643","EFO_0003027","EFO_0003811"],"count":47},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1979 and is indicated for neoplasm and acute myeloid leukemia and has 18 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL178803","canonicalSmiles":"CCN1CCN(c2cc(-c3ccc(F)cc3)c3c(n2)CCCCCC3)CC1","inchiKey":"XVGOZDAJGBALKS-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BLONANSERIN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AD-5423","Blonanserin"],"crossReferences":{"PubChem":["144206818"],"drugbank":["DB09223"]},"count":1,"linkedTargets":{"rows":["ENSG00000149295","ENSG00000102468","ENSG00000151577"],"count":3},"linkedDiseases":{"rows":["EFO_0000692"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL1882685","canonicalSmiles":"CC12CC3CC(C)(C1)CC(N)(C3)C2.O=[N+]([O-])O","inchiKey":"YZQFRDLXENSKCA-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1882685","maximumClinicalTrialPhase":0,"parentId":"CHEMBL807","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["50085467"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1946170","canonicalSmiles":"CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1","inchiKey":"FNHKPVJBJVTLMP-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"REGORAFENIB","yearOfFirstApproval":2012,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Stivarga"],"synonyms":["BAY 73-4506","BAY 73-4506 monohydrate","BAY-73-4506","BAY-734506","Regorafenib"],"crossReferences":{"DailyMed":["regorafenib"],"PubChem":["137275982"],"Wikipedia":["Regorafenib"],"drugbank":["DB08896"],"chEBI":["68647"]},"count":35,"approvedIndications":["EFO_0000616","EFO_0000311"],"linkedTargets":{"rows":["ENSG00000128052","ENSG00000165731","ENSG00000066468","ENSG00000037280","ENSG00000120156","ENSG00000185386","ENSG00000113721","ENSG00000157404","ENSG00000134853","ENSG00000097007","ENSG00000102755","ENSG00000077782","ENSG00000157764","ENSG00000111816","ENSG00000132155","ENSG00000162733"],"count":16},"linkedDiseases":{"rows":["EFO_0000637","EFO_0000365","EFO_0001075","MONDO_0015686","EFO_0000756","EFO_0000681","EFO_1000657","MONDO_0021063","EFO_0000231","EFO_1001951","EFO_0009606","MONDO_0001056","EFO_1001480","EFO_1000218","MONDO_0002158","EFO_1000044","EFO_0003968","EFO_0000389","EFO_0000182","EFO_0005540","MONDO_0044919","EFO_1001949","EFO_0000616","EFO_0002618","EFO_0003893","MONDO_0002108","MONDO_0008170","Orphanet_44890","EFO_0005842","MONDO_0007576","EFO_0000313","EFO_1001968","EFO_0000222","EFO_0005221","EFO_0000311","EFO_0004142","EFO_0000702","EFO_0000691","EFO_0000519","EFO_0000569"],"count":40},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and is indicated for cancer and neoplasm and has 33 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1951714","canonicalSmiles":"CCCCCCCCCCCCCCCCCCCCCCCCCCCCO","inchiKey":"CNNRPFQICPFDPO-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"OCTACOSANOL","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["NSC-10770","Octacosan-1-ol","Octacosanol"],"crossReferences":{"drugbank":["DB11220"],"chEBI":["28243"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1956820","canonicalSmiles":"COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(P(=O)(O)Cc6c(F)cccc6F)C[C@H]5CCCCCCC[C@H](NC(=O)OC5CCCC5)C(=O)N4C3)cc(-c3csc(NC(C)C)n3)nc2c1Cl","inchiKey":"RFGUWOCFYCYEDM-ZOMNBDOOSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GS-9256","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["GS-9256","Gs-9256"],"crossReferences":{"drugbank":["DB12876"]},"count":2,"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL1969664","canonicalSmiles":"N#Cc1ccc2[nH]c(O)c(-c3ccc(CN4CCOCC4)cn3)c2c1","inchiKey":"BLTVBQXJFVRPFK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"AZD-1080","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AZ-11548415","AZD-1080","Azd-1080"],"crossReferences":{"PubChem":["103905163"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL197577","canonicalSmiles":"O=C(O)[C@@H]1C[C@]2(C(=O)O)C=C[C@@H](O)[C@@H](C2)O1","inchiKey":"KRZHNRULRHECRF-JQCUSGDOSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL197577","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08648"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL198362","canonicalSmiles":"O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1","inchiKey":"KGFYHTZWPPHNLQ-AWEZNQCLSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"RIVAROXABAN","yearOfFirstApproval":2011,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Xarelto"],"synonyms":["BAY 59-7939","BAY-59-7939","JNJ-39039039","JNJ39039039","Rivaroxaban"],"crossReferences":{"DailyMed":["rivaroxaban"],"Wikipedia":["Rivaroxaban"],"drugbank":["DB06228"],"chEBI":["68579"]},"count":29,"approvedIndications":["EFO_0000275","MONDO_0000831","EFO_0003827","EFO_0003907","HP_0004419","HP_0004936"],"linkedTargets":{"rows":["ENSG00000126218"],"count":1},"linkedDiseases":{"rows":["EFO_0003777","EFO_0000275","Orphanet_232","EFO_0009531","EFO_0003914","HP_0000083","HP_0030242","EFO_0003144","EFO_0000712","EFO_0003884","EFO_0003837","EFO_0004616","EFO_1001161","HP_0004419","EFO_0000400","HP_0004936","EFO_0000616","EFO_0002689","EFO_0000694","EFO_0001074","HP_0002140","EFO_0001645","EFO_0004286","EFO_0000556","HP_0001873","EFO_0000311","HP_0001907","MP_0001914","EFO_0001422","MONDO_0100096","EFO_0010680","MONDO_0000831","EFO_0003827","EFO_0003907","EFO_0000612","EFO_0001378","EFO_0001360","EFO_0005672","EFO_0004265"],"count":39},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and has 6 approved and 23 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL2016681","canonicalSmiles":"CC(C)(C)S(=O)(=O)N[C@H]1CC[C@H](C(=O)Nc2ccc(C(F)(F)F)cn2)CC1","inchiKey":"WGEWUYACXPEFPO-AULYBMBSSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"VELNEPERIT","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["S-2367","Velneperit"],"crossReferences":{"drugbank":["DB12889"]},"count":1,"linkedTargets":{"rows":["ENSG00000164129"],"count":1},"linkedDiseases":{"rows":["EFO_0001073"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL2040681","canonicalSmiles":"CC[C@H]1CCC[C@H](O[C@H]2CC[C@H](N(C)C)[C@@H](C)O2)[C@@H](C)C(=O)C2=C[C@@H]3[C@@H](C=C[C@@H]4C[C@@H](O[C@@H]5O[C@@H](C)[C@H](OC)[C@@H](OC)[C@H]5OC)C[C@@H]34)[C@@H]2CC(=O)O1.CC[C@H]1CCC[C@H](O[C@H]2CC[C@H](N(C)C)[C@@H](C)O2)[C@@H](C)C(=O)C2=C[C@H]3[C@@H]4C[C@H](O[C@@H]5O[C@@H](C)[C@H](OC)[C@@H](OC)[C@H]5OC)C[C@H]4C(C)=C[C@H]3[C@@H]2CC(=O)O1","inchiKey":"JFLRKDZMHNBDQS-SGSTVUCESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SPINOSAD","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Natroba"],"synonyms":[],"crossReferences":{"DrugCentral":["4623"],"drugbank":["DB08823"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL204086","canonicalSmiles":"N[C@@H](Cc1ccccc1)[C@H](O)CNS(=O)(=O)c1ccc2ccccc2c1","inchiKey":"QSSWSEQPKCCATQ-VQTJNVASSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL204086","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07522"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2087003","canonicalSmiles":"NC(=O)OC[C@@H](O)c1ccccc1Cl","inchiKey":"OLBWFRRUHYQABZ-MRVPVSSYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CARISBAMATE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Carisbamate","JNJ-10234094","RWJ-333369","RWJ-333369-000","YKP-509"],"crossReferences":{"drugbank":["DB12338"]},"count":10,"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications."}
{"id":"CHEMBL2103821","canonicalSmiles":"O=c1ncc(I)cn1[C@H]1C[C@H](O)[C@@H](CO)O1","inchiKey":"XIJXHOVKJAXCGJ-XLPZGREQSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ROPIDOXURIDINE","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["IPD-R","IPDR","NSC-726188","Ropidoxuridine"],"crossReferences":{"drugbank":["DB06485"]},"count":1,"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL2105097","canonicalSmiles":"COc1ccccc1OC(=O)c1ccccc1OC(C)=O","inchiKey":"HSJFYRYGGKLQBT-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GUACETISAL","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Guacetisal"],"crossReferences":{"drugbank":["DB13538"]},"count":2,"description":"Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL2105825","canonicalSmiles":"CCCN(CCC)C(=O)C(CCC(=O)OCCCN1CCN(CCOC(=O)Cc2c(C)n(C(=O)c3ccc(Cl)cc3)c3ccc(OC)cc23)CC1)NC(=O)c1ccccc1","inchiKey":"PTXGHCGBYMQQIG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PROGLUMETACIN","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Proglumetacin","Proglumetacin maleate"],"crossReferences":{"PubChem":["144206876"],"drugbank":["DB13527"],"chEBI":["76263"]},"count":1,"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL2106227","canonicalSmiles":"CCNC1=Nc2ccc(Cl)cc2C(C)(c2ccccc2)O1","inchiKey":"IBYCYJFUEJQSMK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ETIFOXINE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["36-801","Etifoxine","HOE 36801","HOE-36801"],"crossReferences":{"drugbank":["DB08986"]},"count":1,"linkedTargets":{"rows":["ENSG00000109158","ENSG00000145863","ENSG00000011677","ENSG00000187730","ENSG00000151834","ENSG00000145864","ENSG00000166206","ENSG00000182256","ENSG00000022355","ENSG00000102287","ENSG00000094755","ENSG00000268089","ENSG00000113327","ENSG00000163285","ENSG00000186297","ENSG00000163288"],"count":16},"linkedDiseases":{"rows":["EFO_0005230"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL2106996","canonicalSmiles":"CC(C)N1CCOC(c2cccc(C(F)(F)F)c2)C1","inchiKey":"FVYUQFQCEOZYHZ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"OXAFLOZANE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Oxaflozane"],"crossReferences":{"drugbank":["DB13457"]},"count":1,"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL2107337","canonicalSmiles":"Cl.Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21","inchiKey":"UUADYKVKJIMIPA-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ENZASTAURIN HYDROCHLORIDE","maximumClinicalTrialPhase":3,"parentId":"CHEMBL300138","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Enzastaurin hydrochloride","Enzastaurin monohydrochloride"],"count":12,"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 12 investigational indications."}
{"id":"CHEMBL2107431","canonicalSmiles":"C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CCCC[C@@H]4[C@H]3CC[C@@]21C","inchiKey":"YNVGQYHLRCDXFQ-XGXHKTLJSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LYNESTRENOL","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Lynestrenol","Lynoestrenol","NSC-37725"],"crossReferences":{"drugbank":["DB12474"],"chEBI":["31790"]},"description":"Small molecule drug with a maximum clinical trial phase of III."}
{"id":"CHEMBL2108027","drugType":"Protein","blackBoxWarning":true,"name":"DULAGLUTIDE","yearOfFirstApproval":2014,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Trulicity"],"synonyms":["Dulaglutide","LY-2189265","LY2189265"],"crossReferences":{"DailyMed":["dulaglutide"],"DrugCentral":["4885"]},"count":5,"approvedIndications":["EFO_0001360","EFO_0000400"],"linkedTargets":{"rows":["ENSG00000112164"],"count":1},"linkedDiseases":{"rows":["EFO_0004319","EFO_0001359","HP_0001959","HP_0003074","EFO_0001360","EFO_0000400"],"count":6},"description":"Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and is indicated for type ii diabetes mellitus and diabetes mellitus and has 3 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL2108237","drugType":"Unknown","blackBoxWarning":false,"name":"CAPSICUM OLEORESIN","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Capsicum oleoresin","FEMA NO. 2234","Oleoresin capsicum"],"count":1,"description":"Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL2108282","drugType":"Protein","blackBoxWarning":false,"name":"CATRIDECACOG","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Catridecacog"],"crossReferences":{"DrugCentral":["5134"]},"count":3,"approvedIndications":["MP_0001914"],"description":"Protein drug with a maximum clinical trial phase of IV (across all indications) and is indicated for hemorrhage and has 2 investigational indications."}
{"id":"CHEMBL2108302","drugType":"Protein","blackBoxWarning":false,"name":"SPRIFERMIN","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AS-902330","AS902330","Sprifermin"],"count":3,"description":"Protein drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL2108780","drugType":"Small molecule","blackBoxWarning":false,"name":"POLYETHYLENE GLYCOL 4000","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Atpeg 4000","Dulcobalance","Idrolax"],"synonyms":["Macrogol 4000","Polyethylene glycol 4000"],"count":4,"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL2109426","drugType":"Antibody","blackBoxWarning":false,"name":"BIW-8962","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BIW-8962","Biw-8962"],"count":4,"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL2109662","drugType":"Protein","blackBoxWarning":false,"name":"DALANTERCEPT","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ACE-041","Dalantercept","Delantercept"],"count":5,"linkedTargets":{"rows":["ENSG00000263761","ENSG00000163217"],"count":2},"linkedDiseases":{"rows":["EFO_0000681","EFO_0000182","EFO_0004142","EFO_0001378","EFO_0000181"],"count":5},"description":"Protein drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."}
{"id":"CHEMBL2109664","drugType":"Antibody","blackBoxWarning":false,"name":"ELDELUMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BMS-936557","Eldelumab","MDX-1100"],"count":3,"linkedTargets":{"rows":["ENSG00000169245"],"count":1},"linkedDiseases":{"rows":["EFO_0000729","EFO_0000685","EFO_0000384"],"count":3},"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL2219411","canonicalSmiles":"Cl.Cl.N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1","inchiKey":"IPNATXQRPWRHKD-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MOMELOTINIB DIHYDROCHLORIDE","maximumClinicalTrialPhase":1,"parentId":"CHEMBL1078178","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CYT-387 DIHYDROCHLORIDE","CYT387","CYT387 DIHYDROCHLORIDE","Momelotinib dihydrochloride"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2219413","canonicalSmiles":"N=C(N)NCCCCC(=O)Nc1cc(C(F)(F)F)cc(NC(=O)c2cc(C(=O)Nc3cc(C(F)(F)F)cc(NC(=O)CCCCNC(=N)N)c3O[C@@H]3CCNC3)ncn2)c1O[C@@H]1CCNC1","inchiKey":"QPDYBCZNGUJZDK-DNQXCXABSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BRILACIDIN","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Brilacidin","PMX-30063 FREE BASE","PMX30063","PMX30063 FREE BASE"],"crossReferences":{"drugbank":["DB12997"]},"childChemblIds":["CHEMBL4583215","CHEMBL2219420"],"description":"Small molecule drug with a maximum clinical trial phase of II."}
{"id":"CHEMBL222863","canonicalSmiles":"C[C@@H]1O[C@@H](O[C@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@@H](C6=CC(=O)OC6)CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)[C@H](O)[C@H](O)[C@H]1O","inchiKey":"LPMXVESGRSUGHW-HBYQJFLCSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"OUABAIN","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["NSC-25485","Ouabain"],"crossReferences":{"PubChem":["11533037","124883187","124883189","144203575","144205610","144211864","170465763","26753626","26753627","50106811","50106812","85231346","90340653","92092794"],"drugbank":["DB01092"],"chEBI":["472805"]},"childChemblIds":["CHEMBL1889436","CHEMBL1357246"],"description":"Small molecule drug with a maximum clinical trial phase of IV."}
{"id":"CHEMBL226345","canonicalSmiles":"Nc1ncnc2[nH]cnc12","inchiKey":"GFFGJBXGBJISGV-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ADENINE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Adenine","NSC-14666"],"crossReferences":{"PubChem":["144204901","144212425","170465950","26748402","47193680","540768"],"Wikipedia":["Adenine"],"drugbank":["DB00173"],"chEBI":["16708"]},"childChemblIds":["CHEMBL539503","CHEMBL1597282"],"count":1,"description":"Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL230172","canonicalSmiles":"CCc1ccc(NS(=O)(=O)c2ccc(F)cc2)c(C(=O)O)c1C","inchiKey":"MGUQWAOYPINSIT-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL230172","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07746"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL232942","canonicalSmiles":"N#CC1=C(c2cc(Cl)cc(Cl)c2)C(=O)N2CCC[C@]12Cc1ccc(C#N)cc1","inchiKey":"TZCXQSNBTXDAJG-QFIPXVFZSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL232942","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB06972"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2336325","canonicalSmiles":"CNC(=O)c1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1","inchiKey":"JUSFANSTBFGBAF-IRXDYDNUSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"VISTUSERTIB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AZD-2014","AZD2014","Azd-2014","Vistusertib"],"crossReferences":{"drugbank":["DB11925"]},"count":20,"linkedTargets":{"rows":["ENSG00000198793"],"count":1},"linkedDiseases":{"rows":["EFO_0000616","EFO_0003897","Orphanet_145","EFO_0005232","EFO_1001958","EFO_0000503","MONDO_0015686","EFO_0000349","EFO_0000403","MONDO_0007254","EFO_1001512","EFO_0000708","MONDO_0024879","EFO_0000228","EFO_0003060","MONDO_0008315","EFO_0000311","MONDO_0001187","EFO_0005537","EFO_1000251","EFO_0000702","Orphanet_2495","EFO_0000707","MONDO_0002083","EFO_0000519"],"count":25},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 20 investigational indications."}
{"id":"CHEMBL2364609","canonicalSmiles":"CN[C@]1(c2ccccc2Cl)CCCCC1=O.Cl","inchiKey":"VCMGMSHEPQENPE-ZOWNYOTGSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ESKETAMINE HYDROCHLORIDE","yearOfFirstApproval":2019,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL395091","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Spravato"],"synonyms":["AM-101","Esketamine hydrochloride"],"crossReferences":{"DailyMed":["esketamine%20hydrochloride"],"chEBI":["60800"]},"count":3,"approvedIndications":["EFO_0003761"],"linkedTargets":{"rows":["ENSG00000161509","ENSG00000273079","ENSG00000116032","ENSG00000183454","ENSG00000105464","ENSG00000176884","ENSG00000198785"],"count":7},"linkedDiseases":{"rows":["HP_0000360","EFO_0003761","EFO_0003843"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for unipolar depression and has 2 investigational indications."}
{"id":"CHEMBL2364611","canonicalSmiles":"Cc1cccc(-c2nn3c(c2-c2ccnc4ccc(C(N)=O)cc24)CCC3)n1","inchiKey":"IVRXNBXKWIJUQB-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GALUNISERTIB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Galunisertib","LY-2157299","LY2157299","Ly-2157299"],"crossReferences":{"drugbank":["DB11911"]},"count":11,"linkedTargets":{"rows":["ENSG00000106799"],"count":1},"linkedDiseases":{"rows":["EFO_0000198","EFO_1000412","EFO_0000616","EFO_0002618","EFO_1000657","EFO_0004252","EFO_0000305","MONDO_0008315","EFO_0009708","EFO_1001480","EFO_0003860","EFO_0000182","EFO_0000326","EFO_0000519"],"count":14},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 11 investigational indications."}
{"id":"CHEMBL245079","canonicalSmiles":"CC1=C[C@H]2Cc3[nH]c(=O)ccc3[C@]3(C1)NCCC[C@H]23","inchiKey":"YYWGABLTRMRUIT-HWWQOWPSSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"HUPERZINE B","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB03348"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL249120","canonicalSmiles":"Cc1ccc(C)c(N)c1","inchiKey":"VOWZNBNDMFLQGM-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"2,5-XYLIDINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["2,5-Xylidine"],"crossReferences":{"PubChem":["144208223","17389378","81066855"],"Wikipedia":["2,5-Xylidine"],"drugbank":["DB02163"],"chEBI":["518305"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL250409","canonicalSmiles":"CC(C)(C)NS(=O)(=O)c1ccc(-c2cnc3cccc(Nc4ccccn4)c3c2)cc1","inchiKey":"GJTCKUKIFXWJKG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL250409","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB06933"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL253838","canonicalSmiles":"NC1(c2ccccc2)CCCCC1","inchiKey":"RGZGRPPQZUQUCR-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"1-Phenylcyclohexanamine","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["1-Phenylcyclohexanamine"],"crossReferences":{"drugbank":["DB01506"]},"childChemblIds":["CHEMBL545639"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL256147","canonicalSmiles":"CNC(=N)NCCC[C@H](N)C(=O)O","inchiKey":"NTNWOCRCBQPEKQ-YFKPBYRVSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TILARGININE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["L-NMMA","Ng-methylarginine","Targinine","Tilarginine"],"crossReferences":{"PubChem":["11111490","11113694","90340995"],"Wikipedia":["Methylarginine"],"drugbank":["DB11815"],"chEBI":["28229"]},"childChemblIds":["CHEMBL3217190","CHEMBL1256175","CHEMBL1744478"],"count":8,"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications."}
{"id":"CHEMBL257158","canonicalSmiles":"CC1=N[C@H]2[C@H](O[C@H](CO)[C@@H](O)[C@@H]2O)S1","inchiKey":"DRHXTSWSUAJOJZ-FMDGEEDCSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"N-Acetylglucosamine Thiazoline","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["N-Acetylglucosamine Thiazoline"],"crossReferences":{"drugbank":["DB03747"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL260402","canonicalSmiles":"COC(=O)c1cncn1[C@H](C)c1ccc(I)cc1","inchiKey":"KECBLXVYTIVCTG-SECBINFHSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"IODOMETOMIDATE I-123, R-","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["123i-iodometomidate","Iodometomidate i-123, r-"],"crossReferences":{"drugbank":["DB13021"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL26128","canonicalSmiles":"O=P(O)(O)Oc1ccccc1","inchiKey":"CMPQUABWPXYYSH-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PHENYL DIHYDROGEN PHOSPHATE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Phosphoric Acid Monophenyl Ester"],"crossReferences":{"PubChem":["144212125"],"drugbank":["DB03298"],"chEBI":["37548"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL276443","canonicalSmiles":"CCNC(C)Cc1ccccc1","inchiKey":"YAGBSNMZQKEFCO-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ETILAMFETAMINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Etilamfetamine"],"crossReferences":{"Wikipedia":["Etilamfetamine"],"drugbank":["DB13285"]},"childChemblIds":["CHEMBL1976895"],"count":1,"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL279107","canonicalSmiles":"O=P(O)(O)O[C@H]1[C@H](O)[C@@H](OP(=O)(O)O)[C@H](OP(=O)(O)O)[C@@H](O)[C@H]1O","inchiKey":"MMWCIQZXVOZEGG-XJTPDSDZSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"INS(1,4,5)P3","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["1,4,5-InsP3","Ionositol 1,4,5-Triphosphate"],"crossReferences":{"drugbank":["DB03401"],"chEBI":["16595"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL286398","canonicalSmiles":"CC(O)CO","inchiKey":"DNIAPMSPPWPWGF-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PROPYLENE GLYCOL","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Sentry propylene glycol","Sirlene"],"synonyms":["E1520","E490","FEMA NO. 2940","NSC-69860","Propylene glycol","Propylene glycol cefatrizine","Propylene glycol dl-form"],"crossReferences":{"PubChem":["144209010","144210326","144211758","17389749","49816670"],"Wikipedia":["Propylene_glycol"],"drugbank":["DB01839"],"chEBI":["16997"]},"count":3,"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL296468","canonicalSmiles":"CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1","inchiKey":"OUSFTKFNBAZUKL-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BMS-387032","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BMS-387032","Bms-387032","SNS-032","Sns 032"],"crossReferences":{"PubChem":["103905658","137276011","50100091"],"drugbank":["DB05969"]},"count":4,"linkedTargets":{"rows":["ENSG00000123374","ENSG00000134058","ENSG00000136807"],"count":3},"linkedDiseases":{"rows":["EFO_0000616","EFO_0000095","EFO_0001378","EFO_1001469"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL299175","canonicalSmiles":"COc1cc(CC2NCCc3cc(O)c(O)cc32)cc(OC)c1OC","inchiKey":"RGVPOXRFEPSFGH-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TRETOQUINOL","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AQ-110","Tretoquinol","Trimethoquinol","Trimetoquinol hydrochloride"],"childChemblIds":["CHEMBL542101"],"count":1,"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL3039542","drugType":"Protein","blackBoxWarning":false,"name":"CIMAGLERMIN ALFA","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Cimaglermin alfa","GGF2","RHGGF-2","rhGGF2"],"count":1,"description":"Protein drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL3137685","drugType":"Small molecule","blackBoxWarning":false,"name":"NEDAPLATIN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["NSC-375101D","Nedaplatin"],"crossReferences":{"chEBI":["31898"]},"count":7,"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications."}
{"id":"CHEMBL313972","canonicalSmiles":"C[C@@H](Cc1ccc(O)c(O)c1)[C@H](C)Cc1ccc(O)c(O)c1","inchiKey":"HCZKYJDFEPMADG-TXEJJXNPSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MASOPROCOL","yearOfFirstApproval":1992,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Actinex"],"synonyms":["CHX-100","INSM-18","MESO-NDGA","Masoprocol","Meso-nordihydroguaiaretic acid","NSC-4291","NSC-682984","Nordihydroguaiaretic acid"],"crossReferences":{"PubChem":["11111540","11111541","124891671","144203761","50100292","50106727","50106728","90341429"],"Wikipedia":["Masoprocol"],"drugbank":["DB00179"],"chEBI":["73468"]},"count":2,"approvedIndications":["EFO_0000616"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and is indicated for neoplasm and has 1 investigational indication."}
{"id":"CHEMBL3186027","canonicalSmiles":"CC(CC=O)CCCC(C)(C)O","inchiKey":"WPFVBOQKRVRMJB-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL3186027","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["144206234","144211491","225144317"],"drugbank":["DB14187"],"chEBI":["53459"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL324547","canonicalSmiles":"CNc1cccc(NC(=O)N[C@@H]2N=C(c3ccccn3)c3ccccc3N(CC(=O)C(C)(C)C)C2=O)c1","inchiKey":"YDZYKNJZCVIKPP-VWLOTQADSA-N","drugType":"Protein","blackBoxWarning":false,"name":"NETAZEPIDE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Netazepide","YF-476","Yf476"],"crossReferences":{"drugbank":["DB12355"]},"count":5,"linkedTargets":{"rows":["ENSG00000110148"],"count":1},"linkedDiseases":{"rows":["EFO_0000280","EFO_0004243","EFO_0007549","EFO_1001095","EFO_0008533"],"count":5},"description":"Protein drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."}
{"id":"CHEMBL3301594","canonicalSmiles":"COc1cnc(-n2cnc(C)n2)c2c1c(C(=O)C(=O)N1CCN(C(=O)c3ccccc3)CC1)cn2COP(=O)(O)O","inchiKey":"SWMDAPWAQQTBOG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FOSTEMSAVIR","yearOfFirstApproval":2020,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["BMS-663068","Fostemsavir"],"crossReferences":{"DailyMed":["fostemsavir%20tromethamine"],"drugbank":["DB11796"]},"childChemblIds":["CHEMBL3301598"],"count":2,"approvedIndications":["EFO_0000764","EFO_0000180"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for hiv-1 infection and hiv infection."}
{"id":"CHEMBL3337527","canonicalSmiles":"CCCCn1ccc(N2CCC(c3ccccc3)CC2)c(Cl)c1=O","inchiKey":"HYOGJHCDLQSAHX-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"JNJ-40411813","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ADX-71149","Jnj-40411813"],"crossReferences":{"drugbank":["DB12059"]},"count":3,"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL346631","canonicalSmiles":"CC(C)OCc1ccc2c(c1)c1c3c(c4c(c1n2CCCOC(=O)CN(C)C)Cc1ccccc1-4)C(=O)NC3","inchiKey":"UHEBDUAFKQHUBV-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CEP-7055","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CEP-7055","Cep-7055"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL351132","canonicalSmiles":"Cc1cc2nc[nH]c2cc1C","inchiKey":"LJUQGASMPRMWIW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DIMEDAZOL","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["5,6-Dimethylbenzimidazole","Dimedazol"],"crossReferences":{"drugbank":["DB02591"],"chEBI":["15890"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3526905","canonicalSmiles":"COc1ccc2nc(COc3ccc(CC4SC(=O)NC4=O)cc3)n(C)c2c1.Cl","inchiKey":"LKKAMJRUPIIUTC-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL3526905","maximumClinicalTrialPhase":0,"parentId":"CHEMBL2104753","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3544966","canonicalSmiles":"O=C1NC(=O)/C(=C/c2ccc3nccc(-c4ccncc4)c3c2)S1","inchiKey":"QDITZBLZQQZVEE-YBEGLDIGSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GSK-1059615","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["GSK-615","GSK1059615","GSK615","Gsk-1059615"],"crossReferences":{"drugbank":["DB11962"]},"count":1,"linkedTargets":{"rows":["ENSG00000145675","ENSG00000171608","ENSG00000105647","ENSG00000141506","ENSG00000051382","ENSG00000121879","ENSG00000105851","ENSG00000117461"],"count":8},"linkedDiseases":{"rows":["EFO_0000616"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL3545010","canonicalSmiles":"CCN1CCC(c2cccc(S(C)(=O)=O)c2F)CC1","inchiKey":"UKUPJASJNQDHPH-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ORDOPIDINE","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ACR-325","ACR325","Acr325","Ordopidine"],"count":1,"linkedTargets":{"rows":["ENSG00000149295"],"count":1},"linkedDiseases":{"rows":["EFO_0002508"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL3545159","drugType":"Small molecule","blackBoxWarning":false,"name":"R-333","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["R-333"],"count":1,"linkedTargets":{"rows":["ENSG00000165025","ENSG00000105639"],"count":2},"linkedDiseases":{"rows":["EFO_0002690"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL3545192","drugType":"Antibody","blackBoxWarning":false,"name":"MIRVETUXIMAB","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["M9346A","Mirvetuximab"],"description":"Antibody drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3545369","canonicalSmiles":"NS(=O)(=O)NCCNc1nonc1/C(=N/O)Nc1ccc(F)c(Br)c1","inchiKey":"FBKMWOJEPMPVTQ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"EPACADOSTAT","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Epacadostat","INCB-024360","INCB024360"],"crossReferences":{"drugbank":["DB11717"]},"count":29,"linkedTargets":{"rows":["ENSG00000131203"],"count":1},"linkedDiseases":{"rows":["EFO_0001075","MONDO_0015686","EFO_0000756","EFO_0000681","EFO_1000657","MONDO_0002087","MONDO_0001187","MONDO_0000548","EFO_1001480","EFO_1000044","MONDO_0002158","EFO_0000389","MONDO_0008903","EFO_1000251","EFO_0008528","EFO_0000196","EFO_0000198","EFO_0000616","Orphanet_145","EFO_0006859","EFO_1000616","MONDO_0008170","Orphanet_44890","EFO_1001512","EFO_0000222","MONDO_0044881","EFO_0003060","EFO_0003863","EFO_1000576","MONDO_0000544","EFO_0002517","MONDO_0011962","EFO_0000702","EFO_0000574","MONDO_0024880","EFO_0000691","EFO_0000519","EFO_0000181"],"count":38},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 29 investigational indications."}
{"id":"CHEMBL3545391","canonicalSmiles":"CC#C[C@]1(O)CCC2C3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc4c(c3)OCO4)C[C@@]21C","inchiKey":"DFELGYQKEOCHOA-RBXNTRDFSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ORG-34517","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ORG 34517","Org-34517","SCH 900636","SCH-900636"],"count":2,"linkedTargets":{"rows":["ENSG00000113580"],"count":1},"linkedDiseases":{"rows":["MONDO_0002050","MONDO_0002009"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL3601411","canonicalSmiles":"C[C@H]1C[C@@H](C)CN(S(=O)(=O)c2ccc3c(c2)C(=NO)c2cc(S(=O)(=O)N4C[C@@H](C)C[C@@H](C)C4)ccc2C3=NO)C1","inchiKey":"GAPRVZKWPDRAJA-QOPKLXIQSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TEGAVIVINT","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BC-2059","Tegavivint"],"count":1,"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL360328","canonicalSmiles":"C[C@H]1CNCCc2ccc(Cl)cc21","inchiKey":"XTTZERNUQAFMOF-QMMMGPOBSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LORCASERIN","yearOfFirstApproval":2012,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Lorcaserin"],"crossReferences":{"DailyMed":["lorcaserin%20hydrochloride"],"PubChem":["144206569","170466882"],"Wikipedia":["Lorcaserin"],"drugbank":["DB04871"],"chEBI":["65353"]},"childChemblIds":["CHEMBL3527027","CHEMBL2095211"],"count":10,"approvedIndications":["EFO_0001073"],"linkedTargets":{"rows":["ENSG00000147246"],"count":1},"linkedDiseases":{"rows":["EFO_0007191","EFO_0004319","EFO_0003086","EFO_0004566","EFO_0002610","EFO_0003890","EFO_0003100","EFO_0001421","EFO_0003768","EFO_0000319","EFO_0005611","EFO_0010445","EFO_0001073"],"count":13},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and is indicated for obesity and has 9 investigational indications."}
{"id":"CHEMBL3682589","canonicalSmiles":"O=C(O)c1ccc(S(=O)(=O)N(Cc2ccc(OC(F)(F)F)cc2)c2ncc3ccccc3c2C2CC2)cc1","inchiKey":"CWEFDWIKLABKBX-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ELISMETREP","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Elismetrep","MT-8554","Mt-8554"],"crossReferences":{"drugbank":["DB15287"]},"count":2,"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL3707226","drugType":"Protein","blackBoxWarning":false,"name":"DEFIBROTIDE SODIUM","yearOfFirstApproval":2016,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Defitelio","Defitelio (eu)"],"synonyms":["Defibrotide sodium","JZP-381"],"crossReferences":{"DailyMed":["defibrotide%20sodium"]},"count":1,"approvedIndications":["MONDO_0019514"],"linkedTargets":{"rows":["ENSG00000122194"],"count":1},"linkedDiseases":{"rows":["MONDO_0019514"],"count":1},"description":"Protein drug with a maximum clinical trial phase of IV that was first approved in 2016 and is indicated for hepatic veno-occlusive disease."}
{"id":"CHEMBL3707337","drugType":"Small molecule","blackBoxWarning":false,"name":"FERROUS IODINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Ferrous iodine"],"count":1,"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL371668","canonicalSmiles":"O=C(COP(=O)(O)O)NO","inchiKey":"BAXHHWZKQZIJID-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PHOSPHOGLYCOLOHYDROXAMATE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Phosphoglycolohydroxamate","Phosphoglycolohydroxamic Acid","Phosphoric Acid Monohydroxycarbamoylmethyl Ester"],"crossReferences":{"drugbank":["DB03026"],"chEBI":["28475"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL374478","canonicalSmiles":"CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\\C=C\\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C","inchiKey":"JQXXHWHPUNPDRT-WLSIYKJHSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"RIFAMPIN","yearOfFirstApproval":1971,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Eremfat","Rifadin","Rifampicin","Rifampin","Rimactane"],"synonyms":["BA 411661E","BA-41166E","L-5103","L-5103 LEPETIT","L-5103-LEPETIT","NIH-10782","NSC-113926","Rifampicin","Rifampin","Rifamycin amp"],"crossReferences":{"DailyMed":["rifampin"],"PubChem":["144204882","144208583","144210868","170464760"],"TG-GATEs":["8"],"drugbank":["DB01045"],"chEBI":["28077"]},"count":44,"approvedIndications":["EFO_1000049","Orphanet_3389"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1971 and is indicated for tuberculosis and pulmonary tuberculosis and has 42 investigational indications."}
{"id":"CHEMBL37744","canonicalSmiles":"CN(C)C/C=C(/c1ccc(Br)cc1)c1cccnc1","inchiKey":"OYPPVKRFBIWMSX-SXGWCWSVSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ZIMELDINE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["United Kingdom, Germany"],"classes":["Hepatotoxicity"],"year":1983},"tradeNames":[],"synonyms":["Normud","Zelmid","Zimeldine","Zimelidine"],"crossReferences":{"PubChem":["50104953","90340829"],"Wikipedia":["Zimelidine"],"drugbank":["DB04832"]},"childChemblIds":["CHEMBL2355333","CHEMBL1257002","CHEMBL1257115"],"count":1,"approvedIndications":["EFO_0003761"],"linkedTargets":{"rows":["ENSG00000178394","ENSG00000164270","ENSG00000168830","ENSG00000102468","ENSG00000186090","ENSG00000157219","ENSG00000178084","ENSG00000186038","ENSG00000148680","ENSG00000147246","ENSG00000135312","ENSG00000135914","ENSG00000179546","ENSG00000149305","ENSG00000158748","ENSG00000179097","ENSG00000166736"],"count":17},"linkedDiseases":{"rows":["EFO_0003761"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV and is indicated for unipolar depression. It was withdrawn in United Kingdom, Germany  in 1983 due to Hepatotoxicity."}
{"id":"CHEMBL378927","canonicalSmiles":"Cc1ccc(NS(=O)(=O)c2ccccc2)c(C(=O)O)c1","inchiKey":"HXQLTRSIZRSFTR-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL378927","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07313"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL380589","canonicalSmiles":"CCCCNc1cc(C)nc2nc(Nc3cc(Cl)ccc3C)nn12","inchiKey":"ZTYBIJUAAWLJNU-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL380589","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07128"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3833390","canonicalSmiles":"O.O.O=C([O-])[O-].O[Al](O)O.[Mg+2].[Mg+2].[Mg+2].[OH-].[OH-].[OH-].[OH-]","inchiKey":"MTEOMEWVDVPTNN-UHFFFAOYSA-E","drugType":"Small molecule","blackBoxWarning":false,"name":"ALMAGATE","maximumClinicalTrialPhase":0,"parentId":"CHEMBL1200706","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Almagate","LAS 3876"],"crossReferences":{"DrugCentral":["4435"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL383634","canonicalSmiles":"COc1ccc2c(c1)C(=O)N(CCc1ccc(S(=O)(=O)NC(=O)NC3CCCCC3)cc1)C(=O)C2(C)C","inchiKey":"LLJFMFZYVVLQKT-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GLIQUIDONE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Glurenorm"],"synonyms":["ARDF 26","ARDF-26","Gliquidone"],"crossReferences":{"PubChem":["11112731","144204180","170465581","50085433"],"Wikipedia":["Gliquidone"],"drugbank":["DB01251"]},"count":1,"approvedIndications":["EFO_0000400"],"description":"Small molecule drug with a maximum clinical trial phase of IV and is indicated for diabetes mellitus."}
{"id":"CHEMBL3889654","canonicalSmiles":"O=C(Nc1cnn2ccc(N3CCC[C@@H]3c3cc(F)ccc3F)nc12)N1CC[C@H](O)C1","inchiKey":"NYNZQNWKBKUAII-KBXCAEBGSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LAROTRECTINIB","yearOfFirstApproval":2018,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["ARRY-470","BAY-2757556","BAY2757556","LOXO-101","Larotrectinib","Loxo-101"],"crossReferences":{"DailyMed":["larotrectinib%20sulfate"],"drugbank":["DB14723"]},"childChemblIds":["CHEMBL3989939"],"count":1,"approvedIndications":["EFO_0000616"],"linkedTargets":{"rows":["ENSG00000140538","ENSG00000148053","ENSG00000198400"],"count":3},"linkedDiseases":{"rows":["EFO_0000616","MONDO_0015917","EFO_0000311","EFO_0009708"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2018 and is indicated for neoplasm."}
{"id":"CHEMBL397976","canonicalSmiles":"O=C1CC[C@@H](C(=O)O)N1","inchiKey":"ODHCTXKNWHHXJC-VKHMYHEASA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PIDOLIC ACID","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Pidolic acid"],"crossReferences":{"PubChem":["144205489","170466347","29216300","57260135"],"drugbank":["DB03088"],"chEBI":["18183"]},"childChemblIds":["CHEMBL3707303"],"description":"Small molecule drug with a maximum clinical trial phase of II."}
{"id":"CHEMBL3986824","canonicalSmiles":"Nc1cncc(-c2cn3ccnc3c(Nc3ccc(N4CCN(C5COC5)CC4)cc3)n2)n1","inchiKey":"XCIGZBVOUQVIPI-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LANRAPLENIB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["GS-SYK","Lanraplenib"],"crossReferences":{"drugbank":["DB14770"]},"childChemblIds":["CHEMBL4298174"],"count":4,"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL3989751","drugType":"Small molecule","blackBoxWarning":false,"name":"NEOMYCIN","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Neomycin"],"childChemblIds":["CHEMBL3989602","CHEMBL3989533"],"count":9,"approvedIndications":["EFO_0000771","EFO_0000544","EFO_1001888"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 3 approved and 6 investigational indications."}
{"id":"CHEMBL3990033","drugType":"Oligonucleotide","blackBoxWarning":false,"name":"INCLISIRAN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ALN-60212","ALN-PCSSC","ALN-PSCsc","Inclisiran"],"count":5,"description":"Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."}
{"id":"CHEMBL4079239","canonicalSmiles":"C[C@@H]1c2nnn(-c3ncc(F)cn3)c2CCN1C(=O)c1cccc(C(F)(F)F)c1Cl","inchiKey":"CWFVVQFVGMFTBD-SECBINFHSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"JNJ-54175446","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Jnj-54175446"],"crossReferences":{"drugbank":["DB15358"]},"count":1,"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL410448","canonicalSmiles":"COCCNc1cc(-n2c3c(c4ccccc42)C(=O)CCC3)ccc1C(N)=O","inchiKey":"XQKFKSJUBJPOLY-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL410448","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08557"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL41631","canonicalSmiles":"NCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12","inchiKey":"IDEHCMNLNCJQST-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL41631","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["11110730","11113468","124879160","124879162","26751692","50104383"],"drugbank":["DB04513"]},"childChemblIds":["CHEMBL513116"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL4210847","canonicalSmiles":"CCOCCn1nc(C(=O)NS(C)(=O)=O)c2nc(N(C)CC)nc(Nc3cc(C)ccn3)c21","inchiKey":"ZUHZNKJIJDAJFD-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PF-00489791","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["PF-489,791","Pf-00489791","UK-489,791"],"crossReferences":{"drugbank":["DB11736"]},"count":4,"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL42632","canonicalSmiles":"C[C@H](Nc1ncnc2cc(F)c(F)cc12)C(c1ccccc1)c1ccccc1","inchiKey":"WVGZKPGUHOZIJQ-HNNXBMFYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL42632","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB03678"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL426643","canonicalSmiles":"Cc1cc[nH]c1","inchiKey":"FEKWWZCCJDUWLY-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL426643","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB01932"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL4279455","canonicalSmiles":"CC(=O)O[C@H]1C(=O)[C@]23C[C@H]2C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C","inchiKey":"DXOJIXGRFSHVKA-BZVZGCBYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LAROTAXEL","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Larotaxel","XRP-9881","XRP9881","Xrp9881"],"crossReferences":{"drugbank":["DB12984"]},"count":4,"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL4297184","canonicalSmiles":"Cc1ccc(-c2nc(N)nc3c2nnn3Cc2cccc(CO[C@H]3CCOC3)n2)o1","inchiKey":"KURQKNMKCGYWRJ-HNNXBMFYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CIFORADENANT","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CPI-444","Ciforadenant","V-81444","V81444"],"count":4,"linkedTargets":{"rows":["ENSG00000128271"],"count":1},"linkedDiseases":{"rows":["EFO_0003888","EFO_0002508","EFO_0001378","EFO_0003060"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL4297228","drugType":"Unknown","blackBoxWarning":false,"name":"BRIVOLIGIDE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AYX-1","AYX1","Brivoligide"],"count":1,"description":"Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL4297304","canonicalSmiles":"COc1ccc2nc3c(nc2c1)O[C@@H]1C[C@H]2C(=O)N[C@]4(C(=O)NS(=O)(=O)C5(C)CC5)C[C@H]4/C=C/CCCCC[C@H](NC(=O)O[C@@H]4CCC[C@H]4CCCCC3)C(=O)N2C1","inchiKey":"BLFKRFGLQFYXDF-WAZRELCSSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MK-6325","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["MK 6325","Mk-6325"],"crossReferences":{"drugbank":["DB15249"]},"count":1,"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4297307","canonicalSmiles":"N=C1N(O)[C@@H](COC(N)=O)[C@@H]2N=C(N)N[C@]23N1CCC3(O)O","inchiKey":"PPEKGEBBBBNZKS-HGRQIUPRSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NEOSAXITOXIN","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Neosaxitoxin"],"crossReferences":{"drugbank":["DB12989"]},"count":1,"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4297345","canonicalSmiles":"CCN(CC)C(=O)c1ccc(C2=CC3(CCNCC3)Oc3ccccc32)c(O)c1.Cl","inchiKey":"XROFSGVHHSJMMG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ADL-5747","maximumClinicalTrialPhase":2,"parentId":"CHEMBL561339","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ADL5747","Adl-5747","Adl5747"],"count":1,"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL4297490","canonicalSmiles":"[2H]C([2H])([2H])NC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1","inchiKey":"MLDQJTXFUGDVEO-FIBGUPNXSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CM-4307","maximumClinicalTrialPhase":3,"parentId":"CHEMBL1336","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CM-4307","Cm-4307","Donafenib"],"crossReferences":{"drugbank":["DB15414"]},"count":6,"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."}
{"id":"CHEMBL4297603","canonicalSmiles":"[2H]C([2H])([2H])C(c1cc(C(C)(C)C)c(NC(=O)c2c[nH]c3ccccc3c2=O)cc1O)(C([2H])([2H])[2H])C([2H])([2H])[2H]","inchiKey":"PURKAOJPTOLRMP-ASMGOKTBSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DEUTIVACAFTOR","maximumClinicalTrialPhase":2,"parentId":"CHEMBL2010601","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CTP-656","Ctp-656","Deutivacaftor","VX-561","Vx-561"],"crossReferences":{"drugbank":["DB15141"]},"count":1,"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL4297750","drugType":"Antibody","blackBoxWarning":false,"name":"FARICIMAB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Faricimab","RG7716","RG77161","RO-6867461","RO6867461","Ro6867461"],"count":3,"description":"Antibody drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL4297794","drugType":"Antibody","blackBoxWarning":false,"name":"NEMOLIZUMAB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CIM-331","CIM331","Nemolizumab"],"count":1,"description":"Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL4297827","drugType":"Unknown","blackBoxWarning":false,"name":"SGN-CD352A","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Sgn cd352a","Sgn-cd352a"],"count":1,"description":"Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4297935","drugType":"Unknown","blackBoxWarning":false,"name":"RG-7841","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["DLYE-5953A","DLYE5953A","Dlye5953a","RG-7841","RG7841","Rg-7841"],"count":1,"linkedTargets":{"rows":["ENSG00000261456","ENSG00000188229","ENSG00000104833","ENSG00000137267","ENSG00000160932","ENSG00000258947","ENSG00000101162","ENSG00000196230","ENSG00000137285","ENSG00000176014"],"count":10},"linkedDiseases":{"rows":["EFO_0000616"],"count":1},"description":"Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4297970","drugType":"Antibody","blackBoxWarning":false,"name":"MELRILIMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CNTO-7160","GSK-3772847","GSK3772847","Gsk-3772847","Gsk3772847","Melrilimab"],"count":1,"description":"Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL4298021","drugType":"Antibody","blackBoxWarning":false,"name":"ZAGOTENEMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["LY-3303560","LY3303560","Ly-3303560","Ly3303560","Zagotenemab"],"count":1,"description":"Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL4298034","drugType":"Unknown","blackBoxWarning":false,"name":"MEDI-8852","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["MEDI-8852","MEDI8852","Medi 8852","Medi-8852","Medi8852"],"count":1,"description":"Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL4298058","drugType":"Protein","blackBoxWarning":false,"name":"BEMPEGALDESLEUKIN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Bempegaldesleukin","NKTR-214","NKTR-214 PRODRUG","Nktr 214","Nktr-214"],"count":8,"description":"Protein drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications."}
{"id":"CHEMBL4298095","drugType":"Antibody","blackBoxWarning":false,"name":"NIMACIMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["JNJ-2463","JNJ2463","Nimacimab","RYI-018","RYI018","Ryi-018"],"count":1,"description":"Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL4298210","drugType":"Antibody","blackBoxWarning":false,"name":"ISCALIMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CFZ-533","CFZ533","Iscalimab","NVP-CFZ533"],"count":9,"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 9 investigational indications."}
{"id":"CHEMBL429852","canonicalSmiles":"CC(C)C[C@@H](NC(=N)N)C(=O)NCC(=O)N1CCC(c2cc(-c3ccc(OCc4ccc(C(=O)O)o4)c(Cl)c3Cl)nn2C)CC1","inchiKey":"VNZHOIDQBPFEJU-OAQYLSRUSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SP-4206","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["SP-4206"],"crossReferences":{"drugbank":["DB02581"],"chEBI":["47417"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL454446","canonicalSmiles":"CO/N=C(\\C(=O)N[C@@H]1C(=O)N2C(C(=O)OCOC(=O)C(C)(C)C)=C(/C=C\\c3scnc3C)CS[C@H]12)c1csc(N)n1","inchiKey":"AFZFFLVORLEPPO-UVYJNCLZSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CEFDITOREN PIVOXIL","yearOfFirstApproval":2001,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Meiact","Spectracef"],"synonyms":["CDTR-PI","Cefditoren","Cefditoren pivaloyloxymethyl ester","Cefditoren pivoxil","ME-1207","ME1207"],"crossReferences":{"DailyMed":["cefditoren%20pivoxil"],"PubChem":["144206748"],"chEBI":["560555"]},"count":4,"approvedIndications":["EFO_0006505","HP_0011110","MONDO_0002258"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 3 approved and 1 investigational indication."}
{"id":"CHEMBL4559134","canonicalSmiles":"COc1ccc(CN2C3CC2CN(c2ccc(-c4cc(OCC(C)(C)O)cn5ncc(C#N)c45)cn2)C3)cn1","inchiKey":"XIIOFHFUYBLOLW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SELPERCATINIB","yearOfFirstApproval":2020,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Retevmo"],"synonyms":["LOXO-292","LY-3527723","LY3527723","Loxo-292","Selpercatinib"],"crossReferences":{"DailyMed":["selpercatinib"]},"count":3,"approvedIndications":["MONDO_0002108","EFO_0003060"],"linkedTargets":{"rows":["ENSG00000165731","ENSG00000170759","ENSG00000108091"],"count":3},"linkedDiseases":{"rows":["MONDO_0002108","MONDO_0015277","EFO_0003060"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for thyroid cancer and non-small cell lung carcinoma and has 1 investigational indication."}
{"id":"CHEMBL45816","canonicalSmiles":"COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C","inchiKey":"HBNPJJILLOYFJU-VMPREFPWSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MIBEFRADIL","yearOfFirstApproval":1997,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["United States"," European Union"," Germany"," Ireland"," Malasia"],"classes":["Cardiotoxicity"],"year":1998},"tradeNames":["Posicor 100","Posicor 50"],"synonyms":["Mibefradil","Posicor"],"crossReferences":{"PubChem":["11111472","26755047","50110875","90340964"],"Wikipedia":["Mibefradil"],"drugbank":["DB01388"],"chEBI":["6920"]},"childChemblIds":["CHEMBL1256688","CHEMBL1534525","CHEMBL1421212"],"count":3,"approvedIndications":["EFO_0000319"],"linkedTargets":{"rows":["ENSG00000100346","ENSG00000006283","ENSG00000196557"],"count":3},"linkedDiseases":{"rows":["EFO_0000319","EFO_0000519","EFO_1000158"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for cardiovascular disease and has 2 investigational indications. It was withdrawn in United States,  European Union,  Germany,  Ireland and  Malasia initially in 1998 due to Cardiotoxicity."}
{"id":"CHEMBL4594306","drugType":"Antibody","blackBoxWarning":false,"name":"DILPACIMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ABT-165","Abt 165","Abt-165","Dilpacimab","PR-1283233"],"count":2,"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL46516","canonicalSmiles":"O=C1NCN(c2ccccc2)C12CCN(CCCC(c1ccc(F)cc1)c1ccc(F)cc1)CC2","inchiKey":"QOYHHIBFXOOADH-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FLUSPIRILENE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Imap","Redeptin"],"synonyms":["Fluspirilene","Imap","MCN-JR-6218","R 6218","R-6218","Redeptin"],"crossReferences":{"PubChem":["104171151","11111163","11112501","11532937","124880064","124880066","144203693","170466307","174006661","26753577","26753578","50106303","50106304","56422781","85231040","90341058"],"Wikipedia":["Fluspirilene"],"drugbank":["DB04842"]},"count":5,"approvedIndications":["EFO_0005407"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for psychosis and has 4 investigational indications."}
{"id":"CHEMBL482035","canonicalSmiles":"COC(=O)c1cc(OC)c2c(c1-c1c(CO)cc(OC)c3c1OCO3)OCO2","inchiKey":"KXMTXZACPVCDMH-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BICYCLOL","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Bicyclol"],"count":1,"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL482950","canonicalSmiles":"CC[C@@H](C)Nc1nc(C)nc2c(-c3ccc(OC)nc3C)c(C)nn12","inchiKey":"LBWQSAZEYIZZCE-SNVBAGLBSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PEXACERFONT","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BMS-562086","Bms562086","CRF1 ANTAGONIST","Pexacerfont"],"crossReferences":{"drugbank":["DB12572"]},"count":2,"linkedTargets":{"rows":["ENSG00000120088"],"count":1},"linkedDiseases":{"rows":["EFO_1001892","MONDO_0002009","EFO_0000555"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL483321","canonicalSmiles":"COCC(=O)NC/C=C/c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1","inchiKey":"LLVZBTWPGQVVLW-SNAWJCMRSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CP-724714","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CP-724,714","CP-724714","Cp-724714"],"crossReferences":{"PubChem":["50100096"],"drugbank":["DB12302"]},"count":3,"linkedTargets":{"rows":["ENSG00000141736"],"count":1},"linkedDiseases":{"rows":["EFO_0003869","MONDO_0007254","EFO_0009708"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL483348","canonicalSmiles":"Cc1nc2c(c(=O)[nH]1)CSCC2","inchiKey":"HRYKZAKEAVZGJD-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL483348","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07677"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL485323","canonicalSmiles":"CNC(=O)CN1CCC(Nc2nccc(-c3cnc4ccccn34)n2)CC1","inchiKey":"AJLILYAPRHIFAS-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL485323","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08026"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL497834","canonicalSmiles":"CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@H]3[C@H](CC[C@@]21C)[C@@]1(C)CC[C@H](O)CC1=C[C@@H]3O","inchiKey":"OYXZMSRRJOYLLO-KGZHIOMZSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"7Beta-Hydroxycholesterol","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["7Beta-Hydroxycholesterol"],"crossReferences":{"drugbank":["DB04706"],"chEBI":["42989"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL517427","canonicalSmiles":"COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)C1c1cccc([N+](=O)[O-])c1","inchiKey":"FAIIFDPAEUKBEP-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NILVADIPINE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CL 287,389","CL-287,389","CL-287389","FK 235","FK-235","FR-34235","Nilvadipine","Nivadipine","SK&F 102,362","SKF-102362"],"crossReferences":{"PubChem":["144205992","50112689"],"Wikipedia":["Nilvadipine"],"drugbank":["DB06712"]},"count":2,"linkedTargets":{"rows":["ENSG00000157388","ENSG00000081248","ENSG00000151067","ENSG00000102001"],"count":4},"linkedDiseases":{"rows":["EFO_0000249","EFO_0000319"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL535650","canonicalSmiles":"Cl.OC(c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12)C1CCCCN1","inchiKey":"WESWYMRNZNDGBX-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"MEFLOQUINE HYDROCHLORIDE","yearOfFirstApproval":1989,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL416956","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Fansimef","Lariam","Mefloquine hydrochloride"],"synonyms":["Mefloquine hydrochloride","RO 21-5998/001"],"crossReferences":{"DailyMed":["mefloquine%20hydrochloride"],"PubChem":["56463353"]},"count":2,"approvedIndications":["EFO_0007444","EFO_0007445"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and is indicated for plasmodium falciparum malaria and plasmodium vivax malaria. This drug has a black box warning from the FDA."}
{"id":"CHEMBL595573","canonicalSmiles":"O=C1O[C@]2(CC[C@H](C(=O)Nc3ccn(-c4ccccc4F)n3)CC2)c2cnccc21","inchiKey":"RMYZIRFUCOMQRH-CAJLXGCNSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MK-0557","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["MK-0557","MK0557","Mk-0557","Mk0557"],"crossReferences":{"drugbank":["DB12168"]},"count":2,"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL65273","canonicalSmiles":"N[C@H](Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)NCCNc1ccncc1","inchiKey":"GEIDRYBJURDUSW-MOPGFXCFSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL65273","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08422"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL67166","canonicalSmiles":"CCCCCCCCCCCCC/C=C/[C@@H](O)[C@@H](N)CO","inchiKey":"WWUZIQQURGPMPG-KRWOKUGFSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SPHINGOSINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["D-Sphingosine"],"crossReferences":{"PubChem":["124384872","26751809","26751810","26751811","50104502","50104503","50104504","56320653"],"Wikipedia":["Sphingosine"],"drugbank":["DB03203"],"chEBI":["16393"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL679","canonicalSmiles":"CNC[C@H](O)c1ccc(O)c(O)c1","inchiKey":"UCTWMZQNUQWSLP-VIFPVBQESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"EPINEPHRINE","yearOfFirstApproval":1965,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Adren co","Adrenaclick","Adrenalin","Ana-Kit","Ana-guard","Anapen","Anaphylactic shock drug kit","Asma-vydrin","Asthmahaler","Auvi-q","Bronkaid mist","Brovon","Emerade","Epi e z pen jr","Epinephrine","Epinephrine (copackaged)","Epipen","Epipen e z pen","Epipen jr","Epipen jr.","Eppy","Gppe inh soln","Jext","Medihaler-epi","Primatene","Primatene mist","Riddobron","Riddofan","Rybarvin","Simplene","Soln made to rybarvin for","Sus-Phrine","Sus-Phrine Sulfite-Free","Sus-phrine sulfite free","Symjepi","Twinject 0.15","Twinject 0.3"],"synonyms":["Adrenaline","Epinephrine","Epinephrine hydrochloride","Levo-methylaminoethanolcatechol","NSC-62786","Twinject"],"crossReferences":{"DailyMed":["epinephrine","epinephrine%20bitartrate"],"PubChem":["11111154","144205115","170464973","26754418","26754419","26754420","29215202","90341589"],"Wikipedia":["Epinephrine"],"drugbank":["DB00668"],"chEBI":["28918"]},"childChemblIds":["CHEMBL3183376","CHEMBL1256958","CHEMBL1200818","CHEMBL227634"],"count":38,"approvedIndications":["EFO_0005854","MP_0001914","HP_0006536","EFO_0005531","EFO_0007486","EFO_0000270","EFO_0004278","EFO_0000319","EFO_0000516","EFO_0005532","HP_0001742","EFO_0009492","EFO_0003956"],"linkedTargets":{"rows":["ENSG00000274286","ENSG00000184160","ENSG00000169252","ENSG00000171873","ENSG00000170214","ENSG00000120907","ENSG00000043591","ENSG00000188778","ENSG00000150594"],"count":9},"linkedDiseases":{"rows":["HP_0002105","EFO_1001139","EFO_0009540","HP_0002239","EFO_1001178","EFO_0007486","EFO_0004278","MONDO_0003061","HP_0011950","HP_0100543","EFO_0002506","EFO_0000544","EFO_1000786","EFO_0005306","EFO_1000652","EFO_0004616","EFO_0009552","EFO_0000400","EFO_1001250","EFO_0005854","HP_0002619","HP_0001742","EFO_0000546","MP_0001914","HP_0006536","EFO_1000391","EFO_0000270","EFO_0004209","EFO_0000516","HP_0031273","EFO_0003033","EFO_0009676","EFO_0005251","EFO_0004610","EFO_0001059","EFO_0006834","MONDO_0007254","EFO_0008553","EFO_0002950","MONDO_0001056","EFO_0005531","MONDO_0022394","MONDO_0002050","HP_0001385","EFO_0003144","EFO_1001417","EFO_0000616","EFO_0004269","EFO_0004198","EFO_0000319","EFO_0005532","EFO_0003843","EFO_0003060","EFO_0007227","EFO_0004287","EFO_0000649","EFO_1001087","MONDO_0021400","EFO_0009492","EFO_0003956"],"count":60},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1965 and has 13 approved and 25 investigational indications."}
{"id":"CHEMBL82321","canonicalSmiles":"Nc1cccc2cc3ccccc3cc12","inchiKey":"YUENFNPLGJCNRB-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"1-Aminoanthracene","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["1-Aminoanthracene","Anthracen-1-Ylamine"],"crossReferences":{"Wikipedia":["Anthramine"],"drugbank":["DB01976"],"chEBI":["40678"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL847","canonicalSmiles":"CC(C)NCC1CCc2cc(CO)c([N+](=O)[O-])cc2N1","inchiKey":"XCGYUJZMCCFSRP-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"OXAMNIQUINE","yearOfFirstApproval":1980,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Vansil"],"synonyms":["Oxamniquine","UK-4271"],"crossReferences":{"PubChem":["144204144","26665195"],"Wikipedia":["Oxamniquine"],"drugbank":["DB01096"],"chEBI":["78416"]},"count":1,"approvedIndications":["EFO_1001342"],"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1980 and is indicated for helminthiasis."}
{"id":"CHEMBL88","canonicalSmiles":"O=P1(N(CCCl)CCCl)NCCCO1","inchiKey":"CMSMOCZEIVJLDB-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CYCLOPHOSPHAMIDE","yearOfFirstApproval":1959,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Cytoxan"],"synonyms":["Cyclophosphamide","Cytoxan","Neosar"],"crossReferences":{"DailyMed":["cyclophosphamide"],"PubChem":["174007432","50105634","85230959","87150","90341534"],"TG-GATEs":["24"],"Wikipedia":["Cyclophosphamide"],"drugbank":["DB00531"],"chEBI":["4027"]},"childChemblIds":["CHEMBL1200796","CHEMBL2364721"],"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1959."}
{"id":"CHEMBL960","canonicalSmiles":"Cc1oncc1C(=O)Nc1ccc(C(F)(F)F)cc1","inchiKey":"VHOGYURTWQBHIL-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"LEFLUNOMIDE","yearOfFirstApproval":1998,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Arava","Leflunomide"],"synonyms":["HWA-486","L04AA13","Leflunomide","SU-101","SU101","SULOL"],"crossReferences":{"DailyMed":["leflunomide"],"PubChem":["11111382","11111383","124880563","124880568","144203733","144212190","170464823","174006674","26746985","26746986","26746987","50100264","50104054","50104055","50104056","56422128","85231115","855764","90341277"],"Wikipedia":["Leflunomide"],"drugbank":["DB01097"],"chEBI":["6402"]},"count":18,"approvedIndications":["EFO_0000685","EFO_0000540"],"linkedTargets":{"rows":["ENSG00000102967"],"count":1},"linkedDiseases":{"rows":["MONDO_0013730","EFO_0003073","EFO_0000685","EFO_0005761","EFO_1000965","EFO_0000756","MONDO_0007254","EFO_0003778","EFO_0000540","MONDO_0008315","EFO_0002609","EFO_0007187","EFO_1001231","EFO_0008518","MONDO_0100096","EFO_0002690","Orphanet_238510","EFO_0000764","EFO_0001378","EFO_0004991","EFO_1000158"],"count":21},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and is indicated for rheumatoid arthritis and immune system disease and has 16 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL976","canonicalSmiles":"O=C(C1CCCCC1)N1CC(=O)N2CCc3ccccc3C2C1","inchiKey":"FSVJFNAIGNNGKK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PRAZIQUANTEL","yearOfFirstApproval":1982,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Biltricide","Cesol","Cestocur","Cisticid","Cysticide","Droncit"],"synonyms":["EMBAY 8440","EMBAY-8440","Praziquantel"],"crossReferences":{"DailyMed":["praziquantel"],"PubChem":["144204211","144209148","144213244","170464906","174006188","26747203","50105220","85231186","855582","858012","90341571"],"Wikipedia":["Praziquantel"],"drugbank":["DB01058"]},"count":5,"approvedIndications":["EFO_1001342"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and is indicated for helminthiasis and has 4 investigational indications."}
